Company Name ReVision Therapeutics
Mailing Address 5626 Oberlin Drive San Diego, CA 92121
Company Description ReVision Therapeutics is focused on developing fenretinide for the treatment of age-related macular degeneration (AMD), the leading cause of blindness in the elderly. There are currently no treatments for the dry form of AMD, which accounts for 90% of patients with the disease. AMD gradually destroys sharp, central vision, and is caused by the accumulation of A2E, a toxic byproduct of the visual cycle, in the retina. ReVision’s lead drug candidate, fenretinide, has been shown to reduce the accumulation of A2E in the retina and slow the growth of atrophic lesions, which precede vision loss.